135 related articles for article (PubMed ID: 20632058)
1. Treatment strategy for metastatic breast cancer according to intrinsic subtype.
Noguchi S
Int J Clin Oncol; 2010 Aug; 15(4):333-4. PubMed ID: 20632058
[No Abstract] [Full Text] [Related]
2. Breast cancer and genomic testing.
Liedtke C; Kolberg HC
Br J Surg; 2017 Jun; 104(7):799-801. PubMed ID: 28300277
[No Abstract] [Full Text] [Related]
3. Precision Medicine and Targeted Therapies in Breast Cancer.
Greenwalt I; Zaza N; Das S; Li BD
Surg Oncol Clin N Am; 2020 Jan; 29(1):51-62. PubMed ID: 31757313
[TBL] [Abstract][Full Text] [Related]
4. Treatment strategy for HER2-positive breast cancer.
Mukai H
Int J Clin Oncol; 2010 Aug; 15(4):335-40. PubMed ID: 20632056
[TBL] [Abstract][Full Text] [Related]
5. Clinical Risk During the Evaluation of Genomic Risk for Hormone-Sensitive Breast Cancer: Ignoring Valuable Data.
Khaki AR; Gadi VK; Prasad V
J Natl Compr Canc Netw; 2019 Dec; 17(12):1456-1458. PubMed ID: 31805524
[No Abstract] [Full Text] [Related]
6. Ribociclib in HR-positive, HER2-negative breast cancer.
Burki TK
Lancet Oncol; 2016 Nov; 17(11):e482. PubMed ID: 27746106
[No Abstract] [Full Text] [Related]
7. Clinicopathological features and treatment strategy for triple-negative breast cancer.
Yamamoto Y; Iwase H
Int J Clin Oncol; 2010 Aug; 15(4):341-51. PubMed ID: 20632057
[TBL] [Abstract][Full Text] [Related]
8. HER2-positive breast cancer, intrinsic subtypes, and tailoring therapy.
Ellis MJ
J Natl Cancer Inst; 2014 Aug; 106(8):. PubMed ID: 25139535
[No Abstract] [Full Text] [Related]
9. Precision Medicine in Breast Cancer Care: An Early Glimpse of Impact.
Kurian AW; Friese CR
JAMA Oncol; 2015 Nov; 1(8):1109-10. PubMed ID: 26313021
[No Abstract] [Full Text] [Related]
10. Point: The Imprecise Pursuit of Precision Medicine: Are Biomarkers to Blame?
Gyawali B
J Natl Compr Canc Netw; 2017 Jul; 15(7):859-862. PubMed ID: 28687572
[No Abstract] [Full Text] [Related]
11. Predictive factors for response to cytotoxic treatment in advanced breast cancer: a review.
Sjöström J; Blomqvist C
Acta Oncol; 1996; 35 Suppl 5():84-90. PubMed ID: 9142975
[No Abstract] [Full Text] [Related]
12. Re: potential pitfalls of crossover and thoughts on iniparib in triple-negative breast cancer.
Kane RC
J Natl Cancer Inst; 2012 May; 104(9):717-8; author reply 718. PubMed ID: 22472306
[No Abstract] [Full Text] [Related]
13. Accuracy and precision in HER2/neu testing in breast cancer: are we there yet?
Yaziji H; Gown AM
Hum Pathol; 2004 Feb; 35(2):143-6. PubMed ID: 14991529
[No Abstract] [Full Text] [Related]
14. Clinical and molecular aspects of breast cancer: Targets and therapies.
Godone RLN; Leitão GM; Araújo NB; Castelletti CHM; Lima-Filho JL; Martins DBG
Biomed Pharmacother; 2018 Oct; 106():14-34. PubMed ID: 29945114
[TBL] [Abstract][Full Text] [Related]
15. The triple-negative subtype: new ideas for the poorest prognosis breast cancer.
Curigliano G; Goldhirsch A
J Natl Cancer Inst Monogr; 2011; 2011(43):108-10. PubMed ID: 22043054
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of PIK3CA mutation status, PTEN and androgen receptor expression for metastasis-free survival in HER2-positive breast cancer patients treated with trastuzumab in adjuvant setting.
Adamczyk A; Niemiec J; Janecka A; Harazin-Lechowska A; Ambicka A; Grela-Wojewoda A; Domagała-Haduch M; Cedrych I; Majchrzyk K; Kruczak A; Ryś J; Jakubowicz J
Pol J Pathol; 2015 Jun; 66(2):133-41. PubMed ID: 26247526
[TBL] [Abstract][Full Text] [Related]
17. What is the value of the 21 gene recurrence score in HER2-negative patients?
Rosman M; Mylander WC; Tafra L
J Clin Oncol; 2010 Nov; 28(31):e647; author reply e648. PubMed ID: 20876423
[No Abstract] [Full Text] [Related]
18. Precision medicine in breast cancer: From clinical trials to clinical practice.
Crimini E; Repetto M; Aftimos P; Botticelli A; Marchetti P; Curigliano G
Cancer Treat Rev; 2021 Jul; 98():102223. PubMed ID: 34049187
[TBL] [Abstract][Full Text] [Related]
19. The androgen receptor in breast cancer: learning from the past.
Higgins MJ; Wolff AC
Breast Cancer Res Treat; 2010 Dec; 124(3):619-21. PubMed ID: 20354779
[No Abstract] [Full Text] [Related]
20. Does topoisomerase II-alpha gene amplification provide useful information for treatment selection in patients with breast carcinoma?
Simon R
J Clin Oncol; 2011 Jul; 29(21):2941; author reply 2941-4. PubMed ID: 21670460
[No Abstract] [Full Text] [Related]
[Next] [New Search]
